UNICYCIVE THERAPEUTICS INC (UNCY) Stock Analyst Earnings Estimates
NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 950K | 675K -28.95% | -100.00% | 23.696M | 369.31M 1,458.53% | 807.31M 118.60% | 492.87M -38.95% | 450.59M -8.58% | 465.67M 3.35% | 372.8M -19.94% | 278.89M -25.19% | ||
| EBITDA YoY % growth | -8.98M | -18.04M -100.89% | -20.765M -15.11% | N/A -54.56% | -42.432M -32.21% | 125.77M 396.40% | 577.42M 359.11% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.98M -344.55% | -18.05M -101.00% | -20.774M -15.09% | -30.664M -54.60% | -34.545M -7.56% | 186.24M 639.13% | 537.55M 188.63% | 384.12M -28.54% | 338.75M -11.81% | 348.78M 2.96% | 265.85M -23.78% | 192.91M -27.44% | |
| Operating Margin | N/A | -1,900.00% | -3,077.63% | N/A | -145.78% | 50.43% | 66.59% | 77.94% | 75.18% | 74.90% | 71.31% | 69.17% | |
| EPS YoY % growth | N/A | -12.00 -58.27% | -16.10 -34.17% | -5.14 33.54% | -2.06 80.74% | 8.19 497.28% | 22.19 171.03% | 17.26 -22.18% | 12.95 -24.96% | 12.67 -2.17% | 10.10 -20.32% | 6.19 -38.72% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.75 49.68% | -0.92 -83.60% | -0.37 85.88% | -0.05 89.80% | 2.24 397.30% | 3.52 483.33% | 3.77 1,127.78% |
| Revenue Q2Q % growth | 433.5K | 20.805M | 33.254M | 69.026M | 105.41M 24,216.03% | 134.36M 545.81% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.615M -29.92% | -11.777M -88.39% | -8.867M 4.25% | 11.855M 226.02% | 37.908M 494.25% | 62.728M 632.65% | 82.352M 1,028.70% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.50 91.80% | -0.67 | 0.17 | 25.73% |
| Q4 2024 Q2Q % growth | -2.60 -18.18% | -0.92 | -1.68 | -183.22% |
| Q3 2024 Q2Q % growth | -0.50 61.54% | -1.55 | 1.05 | 67.68% |
| Q2 2024 Q2Q % growth | -1.50 48.28% | -1.96 | 0.46 | 23.27% |
| Q1 2024 Q2Q % growth | -6.10 37.11% | -1.58 | -4.52 | -285.83% |
| Q4 2023 Q2Q % growth | -2.20 37.14% | -1.71 | -0.49 | -28.77% |
| Q3 2023 Q2Q % growth | -1.30 64.86% | -1.22 | -0.08 | -6.21% |
| Q2 2023 Q2Q % growth | -2.90 -20.83% | -3.47 | 0.57 | 16.38% |
| Q1 2023 Q2Q % growth | -9.70 -304.17% | -3.80 | -5.90 | -155.30% |
| Q4 2022 Q2Q % growth | -3.50 -45.83% | -2.49 | -1.01 | -40.63% |
| Q3 2022 Q2Q % growth | -3.70 -362.50% | -2.86 | -0.84 | -29.55% |
| Q2 2022 Q2Q % growth | -2.40 -84.62% | -2.31 | -0.09 | -3.80% |
| Q1 2022 Q2Q % growth | -2.40 | -1.68 | -0.72 | -42.60% |
| Q4 2021 Q2Q % growth | -2.40 | -1.38 | -1.02 | -74.29% |
| Q3 2021 Q2Q % growth | -0.80 | -1.07 | 0.27 | 25.30% |
| Q2 2021 Q2Q % growth | -1.30 | -1.12 | -0.18 | -15.86% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | 675K | 382.5K | 292.5K | 76.47% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -780% | 0% | -641.28% |
| Revenue | N/A | N/A | 0% | 12.06% |